NCT03821168

The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 58 (estimated)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened . Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years . How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches. In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.

Conditions

• Refractory Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	injection of bevacizumab and erythropoietin	injection of bevacizumab and erythropoietin
DRUG	injection of bevacizumab	under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness

Timeline

• Start date: 2019-03-01
• Primary completion: 2019-04-01
• Completion: 2019-10-01
• First posted: 2019-01-29
• Last updated: 2019-02-05

Locations

1 site across 1 country: Iran